{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:00:35Z","timestamp":1761181235541,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"am","delay-in-days":217,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jbspin.2021.105184","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T06:56:31Z","timestamp":1618901791000},"page":"105184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An update on recent randomized clinical trials in systemic sclerosis"],"prefix":"10.1016","volume":"88","author":[{"given":"Gon\u00e7alo","family":"Boleto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105184_bib0305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"10.1016\/j.jbspin.2021.105184_bib0310","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jbspin.2021.105184_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study","author":"Jaeger","year":"2016","journal-title":"PLoS One [Internet]"},{"key":"10.1016\/j.jbspin.2021.105184_bib0320","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105184_bib0325","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jbspin.2019.09.015","article-title":"Systemic sclerosis: Recent insight in clinical management","volume":"87","author":"Zanatta","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0330","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2665-9913(20)30007-2","article-title":"Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials","volume":"2","author":"Galdo","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105184_bib0335","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2019.11.008","article-title":"Stem cells: Hope for systemic sclerosis patients?","volume":"87","author":"Allanore","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0340","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105184_bib0345","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.=","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105184_bib0355","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105184_bib0360","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105184_bib0365","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105184_bib0370","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105184_bib0375","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.175.8.5390","article-title":"TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis","volume":"175","author":"Bonniaud","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0380","first-page":"146","article-title":"Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial","volume":"36","author":"Mantero","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0385","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","article-title":"T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis","volume":"20","author":"Boleto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105184_bib0390","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3389\/fimmu.2018.02998","article-title":"Targeting Costimulatory Pathways in Systemic Sclerosis","volume":"9","author":"Boleto","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0395","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2021.105184_bib0400","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105184_bib0405","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105184_bib0410","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"10.1016\/j.jbspin.2021.105184_bib0415","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.jbspin.2021.105184_bib0420","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2021.105184_bib0425","unstructured":"Genentech: Press Releases | Thursday, Mar 4, 2021 [Internet]. [cited 2021 Mar 5]. Available from: https:\/\/www.gene.com\/media\/press-releases\/14897\/2021-03-04\/genentechs-actemra-becomes-the-first-bio."},{"key":"10.1016\/j.jbspin.2021.105184_bib0430","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","article-title":"Role of IL-13 in systemic sclerosis","volume":"56","author":"Fuschiotti","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0435","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jbspin.2021.105184_bib0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"10.1016\/j.jbspin.2021.105184_bib0445","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105184_bib0450","unstructured":"Khanna D, Bush E, Nagaraja V, Koenig A, Khanna P, Young A, et al. Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis\u2013 Results of Phase I\/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial [Internet]. ACR Meeting Abstracts [cited 2021 Jan 19]. Available from: https:\/\/acrabstracts.org\/abstract\/tofacitinib-in-early-diffuse-cutaneous-systemic-sclerosis-results-of-phase-i-ii-investigator-initiated-double-blind-randomized-placebo-controlled-trial\/."},{"key":"10.1016\/j.jbspin.2021.105184_bib0455","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.jbspin.2021.105184_bib0460","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0465","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2021.105184_bib0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbalip.2012.06.014","article-title":"Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling","volume":"1831","author":"Zhao","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jbspin.2021.105184_bib0475","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2021.105184_bib0480","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.30262","article-title":"Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma","volume":"63","author":"Castelino","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105184_bib0485","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/exd.12752","article-title":"Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin","volume":"24","author":"Ohashi","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0490","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0495","unstructured":"Khanna D, Denton C, Furst D, Mayes M, Matucci-Cerinic M, Smith V, et al. A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA) [Internet]. ACR Meeting Abstracts [cited 2021 Mar 2]. Available from: https:\/\/acrabstracts.org\/abstract\/a-phase-2a-randomized-double-blind-placebo-controlled-study-of-ziritaxestat-in-early-diffuse-cutaneous-systemic-sclerosis-novesa\/."},{"key":"10.1016\/j.jbspin.2021.105184_bib0500","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2021.105184_bib0505","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105184_bib0510","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2021.105184_bib0515","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2021.105184_bib0520","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0525","unstructured":"FDA approves nintedanib for systemic sclerosis-associated ILD [Internet]. [cited 2021 Jan 25]. Available from: https:\/\/www.healio.com\/news\/pulmonology\/20190906\/fda-approves-nintedanib-for-systemic-sclerosisassociated-ild."},{"key":"10.1016\/j.jbspin.2021.105184_bib0530","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jbspin.2021.105184_bib0535","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105184_bib0540","unstructured":"Spiera R, Hummers L, Chung L, Frech T, Domsic R, Hsu V, et al. Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects [Internet]. ACR Meeting Abstracts [cited 2021 Jan 21]. Available from: https:\/\/acrabstracts.org\/abstract\/safety-and-efficacy-of-lenabasum-at-21-months-in-an-open-label-extension-of-a-phase-2-study-in-diffuse-cutaneous-systemic-sclerosis-subjects\/."},{"key":"10.1016\/j.jbspin.2021.105184_bib0545","unstructured":"Corbus\u2019 Lenabasum Fails Phase III Trial for Systemic Sclerosis [Internet]. BioSpace [cited 2021 Feb 8]. Available from: https:\/\/www.biospace.com\/article\/corbus-lenabasum-flunks-systemic-sclerosis-trial\/"},{"key":"10.1016\/j.jbspin.2021.105184_bib0550","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105184_bib0555","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","article-title":"Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension","volume":"76","author":"Avouac","year":"2017","journal-title":"Ann Rheum Dis"},{"year":"2019","series-title":"A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis [Internet]. clinicaltrials. gov","author":"Inventiva Pharma","key":"10.1016\/j.jbspin.2021.105184_bib0560"},{"key":"10.1016\/j.jbspin.2021.105184_bib0565","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2021.105184_bib0570","first-page":"53","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2021.105184_bib0575","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.jbspin.2021.105184_bib0580","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/annrheumdis-2017-212489","article-title":"Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators","volume":"77","author":"Matei","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105184_bib0585","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the Treatment of Pulmonary Arterial Hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0590","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jbspin.2021.105184_bib0595","doi-asserted-by":"crossref","first-page":"105081","DOI":"10.1016\/j.jbspin.2020.09.013","article-title":"Ethnic influence on the phenotype of French patients with systemic sclerosis","volume":"88","author":"Steelandt","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105184_bib0600","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis\u2013associated interstitial lung disease: Lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"Journal of Scleroderma and Related Disorders"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:26:47Z","timestamp":1761150407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1297319X21000567"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105184","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on recent randomized clinical trials in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105184"}}